Omnia Kamel

Dr. Omnia Kamel


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2026 in Journal of Arrhythmia
Verified
Journal Article
Open access
OKOmnia Kamel
Omnia Kamel
KSKhalid Sawalha
Khalid Sawalha
MAMohamed Abdelazem
Mohamed Abdelazem
AAAmir Abdelghany
Amir Abdelghany
MEMaha Elsaid
Maha Elsaid
AAAhmed Ammar
Ahmed Ammar
Background: Catheter‐based pulmonary vein isolation (PVI) is an established treatment for atrial fibrillation (AF). While cryoballoon ablation (CBA) is a well‐validated single‐shot thermal technology, pulsed field ablation (PFA) has emerged as a predominantly non‐thermal modality that employs high‐voltage electric fields to achieve selective myocardial ablation, potentially minimizing collateral damage. However, comparative evidence between PFA and CBA remains limited. Objectives: To systematically review and compare the efficacy, safety, and procedural efficiency of PFA versus CBA for PVI. Methods and Results: A structured systematic database search was conducted up to August 2025, following PRISMA guidelines. Eighteen studies ( n = 5638; 2396 PFA and 3242 CBA) were included including two randomized controlled trials. PFA significantly shortened procedure time (mean difference −13.7 min; 95% CI –16.7 to −10.8; p < 0.001), while fluoroscopy time and radiation dose were similar. Both modalities achieved high acute PVI success (95%–100%). At 12‐month follow‐up, PFA showed lower arrhythmia recurrence (OR 0.73; 95% CI 0.59–0.90; p = 0.003) with no difference in redo ablation. Overall complications were fewer with PFA (OR 0.53; 95% CI 0.32–0.87; p < 0.001), largely due to reduced phrenic nerve injury, though cardiac tamponade occurred slightly more often in the PFA group. Subgroup analyzes yielded consistent results in paroxysmal AF and when 3D mapping was used. Conclusion: PFA offers superior procedural efficiency and safety compared with CBA, achieving shorter procedures, fewer complications, and lower arrhythmia recurrence at mid‐term follow‐up. Larger multicentre randomized trials with standardized protocols and long‐term follow‐up are needed to confirm these findings and evaluate evolving PFA technologies.

6 October 2026 in Circulation
Verified
Journal Article
Closed access
EREthan Rowin
Ethan Rowin
BMBarry J. Maron
Barry J. Maron
KSKonstantinos Siontis
Konstantinos Siontis
ATAlbree F. Tower-Rader
Albree F. Tower-Rader
DMDaniele Massera
Daniele Massera
MMMartin S. Maron
Martin S. Maron
BACKGROUND: Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population. METHODS: Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes. RESULTS: A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively. CONCLUSIONS: In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.

21 May 2026 in Echocardiography
Verified
Journal Article
Closed access
AEAmr Yosry Emam
Amr Yosry Emam
DHDina Haroun
Dina Haroun
MAMahmoud Abdelfattah
Mahmoud Abdelfattah
SNShaimaa Nabil
Shaimaa Nabil
AHAhmed Mohamed Nasreldin Elsayed Habib
Ahmed Mohamed Nasreldin Elsayed Habib
MSMahmoud Shaaban
Mahmoud Shaaban

24 May 2024 in EP Europace
Verified
Journal Article
Open access
OKOmnia Kamel
Omnia Kamel
MHM W El Husseny
M W El Husseny
THT Hammouda
T Hammouda
HHH H Hosny
H H Hosny
EAEslam Ahmed
Eslam Ahmed
MYM Y Yacoub
M Y Yacoub
Background: Cardiac tumors are rare cardiac disorders which occur either as primary or secondary tumors. They have a wide variety of clinical presentations from accidental discovery till sudden cardiac death. Manifestations are mainly due to mass effect, local invasion, embolization, or constitutional symptoms. (1) Cardiac tumor related arrhythmias are more often incessant, especially in younger children, and the mechanism can be reentry or triggered automaticity. (2) Arrhythmia management depends on its clinical impact as well as tumor size, site, and nature. Surgical resection is preferred in life threating arrhythmias however, the decision should be tailored. Purpose: To describe our institution’s tailored approach in treatment of cardiac tumors presenting with life threatening ventricular arrhythmias (VAs), including surgical resection, coiling of feeding vessels or even ICD implantation with long term rhythm monitoring. Methods: We reviewed patients with primary cardiac tumors presenting to our center from 2015 to 2023 with emphasis on those with life threatening VAs. Patient records were examined for clinical presentation, ECGs, imaging modalities, histopathological analysis of the resected tumors and interrogation data for those with cardiac implantable electronic devices (CIEDS). Results: Over 8 years, 64 patients were diagnosed to have primary cardiac tumors. Of those, 3.8% (6 patients) presented with life threatening monomorphic VT, half of them were pediatrics. Tissue characterization by CMR and histopathological analysis for the resected tumors revealed: 4 fibromas, one lipoma and one hemangioma. Surface ECGs during VT showed exit at, or close to, the site of the tumor (Table). Total surgical resection was performed in four cases (3 fibromas and one lipoma), one of them (the youngest, 6 months old) died during the postoperative period due to refractory heart failure. Partial resection was done in one patient with fibroma as the tumor involved the majority of RV free wall while the patient with hemangioma underwent coiling of the feeding vessels twice with marked decrease in the tumor size however he had one further episode of VT, so ICD was implanted. Over a mean follow up period of 3 years, four patients had no recurrence of tachycardia as confirmed with implantable loop recorders (ILRs) while the patient with ICD had infrequent episodes. Conclusion: Total surgical resection, albeit risky, is highly effective in eliminating life threatening VAs caused by cardiac tumors. Other modalities like partial resection or coiling of the feeding vessels could be effective in high-risk patients. Devascularization, in our hemangioma case was not totally protective. Finally, ILRs were highly beneficial in confirming long-term freedom of arrhythmia after resection.Table: VT exit, tumor site and typeECG, CMR, angiogram& surgical view

10 April 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
OKOmnia Kamel
Omnia Kamel
MAMohamed Abdelazem
Mohamed Abdelazem
SASherien Awad
Sherien Awad
MSMohamed Sharief
Mohamed Sharief
AAAhmed Ammar
Ahmed Ammar
Differentiating near-field (NF) from far-field (FF) electrograms (EGMs) is essential for accurate mapping and ablation of cardiac arrhythmias. With the advent of high density mapping systems, this distinction has traditionally relied on bipolar voltage analysis and activation mapping, while the evaluation of signal frequency has remained largely underexplored. Recently, a novel algorithm called peak frequency (PF) has been introduced as a complementary tool to conventional mapping strategies. By applying Wavelet transformation (WT), PF enables objective quantification of signal frequency, accurate identification of FF electrograms, and visualization of high frequency components on electro-anatomical maps. This review examines the role of peak frequency in mapping and ablation, spanning from fundamental signal analysis to clinical applications.

1 September 2026 in American Heart Journal Plus: Cardiology Research and Practice
Verified
Journal Article
Open access
MRMohamed S. Riad
Mohamed S. Riad
MAMohamed M. Abdelfadil
Mohamed M. Abdelfadil
MHMostafa Wanees Ahmed El Husseny
Mostafa Wanees Ahmed El Husseny
TTTaha Abd-ElSalam Ashraf Taha
Taha Abd-ElSalam Ashraf Taha
EAEslam Ahmed
Eslam Ahmed
OKOmnia Kamel
Omnia Kamel